Group 1 - The recombinant protein concept sector rose by 2.90%, ranking second among concept sectors, with 41 stocks increasing in value [1][2] - Notable gainers in the sector included Ruizhi Pharmaceutical, which hit a 20% limit up, and other significant increases were seen in Sanyuan Gene (20.76%), Haite Biological (15.28%), and NuoSilande (11.14%) [1][2] - The sector experienced a net inflow of 1.22 billion yuan from main funds, with 33 stocks receiving net inflows, and six stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The leading stocks by net inflow included Zhifei Biological (net inflow of 256 million yuan), Ruizhi Pharmaceutical (235 million yuan), Chengdu XianDao (157 million yuan), and Shenzhou Cell (134 million yuan) [2][3] - The top three stocks by net inflow ratio were Shenzhou Cell (19.31%), Kaiyin Technology (16.57%), and Chengdu XianDao (16.19%) [3] - The overall market saw various concept sectors with mixed performances, with CRO concept leading at 4.00% increase, while sectors like pork and chicken saw declines of -1.35% and -1.12% respectively [2]
重组蛋白概念上涨2.90%,6股主力资金净流入超5000万元